Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Paclitaxel poliglumex active, well tolerated in androgen-independent prostate cancer

March 1, 2007

Roche and Kosan advance second-generation epothilone into phase II

March 1, 2007

BiPar Series B financing to support PARP inhibitor development

March 1, 2007

Vandetanib begins new phase III trial with pemetrexed for NSCLC

March 1, 2007

Phase III study of glufosfamide in pancreatic cancer misses endpoint

Feb. 28, 2007

Novelix licenses NVX-207 to AOP Orphan

Feb. 28, 2007

Bristol-Myers Squibb and Adnexus to develop oncology compounds

Feb. 28, 2007

NextPharma signs development agreement with Eucodis

Feb. 28, 2007

ASCENT results support evaluation of calcitriol/docetaxel in prostate cancer

Feb. 27, 2007

Pro-Pharmaceuticals to discuss Davanat NDA with FDA

Feb. 27, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 9, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...